title: Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
authors.forename: Mike
authors.initials: M
authors.lastname: Mitka
mesh_terms: D026683:Advisory Committees; D003657:Decision Making; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced*; D018570:Risk Assessment; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone